AlphaTON Capital Corp
AlphaTON Capital Corp (ATON): 5 pipeline candidates · 25 upcoming catalysts · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
3.9 months
D/E 2.44 · 0% dilution
Lead: Approved
5 candidates
25 upcoming, next in ~9d
N/A
A transparent, data-derived signal for AlphaTON Capital Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.5M
Cash
$200K
Quarterly Burn
$4.5M
Runway
3.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| bupropion | Approved |
| bupropion hydro | Approved |
| celecoxib | Approved |
| lidocaine | Approved |
| risperidone | Approved |
Upcoming Catalysts (25)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$954K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 2,072,103 | $655K |
| shay capital llc | 612,300 | $193K |
| one68 global capital, llc | 112,000 | $35K |
| prelude capital management, llc | 85,000 | $27K |
| warberg asset management llc | 42,133 | $14K |
| xtx topco ltd | 23,241 | $7K |
| two sigma securities, llc | 21,275 | $7K |
| qtr family wealth, llc | 19,272 | $6K |
| norden group llc | 12,506 | $4K |
| jane street group, llc | 11,381 | $4K |
Showing top 10 of 21 institutional holders of AlphaTON Capital Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AlphaTON Capital Corp's pipeline?
AlphaTON Capital Corp (ATON) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AlphaTON Capital Corp's lead drug candidate?
AlphaTON Capital Corp's most advanced tracked candidate is bupropion (Approved) for 1 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) ( 1.1 ) prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulat.
What is AlphaTON Capital Corp's next catalyst?
AlphaTON Capital Corp's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: APLENZIN" — expected June 27, 2026.
What is AlphaTON Capital Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AlphaTON Capital Corp has approximately 3.9 months of cash runway.
What is AlphaTON Capital Corp's market capitalization?
AlphaTON Capital Corp's market capitalization is approximately $7.5M.
Get the full picture on AlphaTON Capital Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.